Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-ethnic study of atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 3, 2010, Pages 628-633

  Yeboah, Joseph ^a   McNamara, Coleen ^a   Jiang, Xian Cheng ^b   Tabas, Ira ^c   Herrington, David M ^d   Burke, Gregory L ^e   Shea, Steven ^c  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c Columbia University School of Medicine ^*  (United States)

^d Department of Internal Medicine/Cardiology ^*  (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary heart disease events; Epidemiology; Plasma sphingomyelin; Prognosis

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A LYASE; SPHINGOMYELIN; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; ANGINA PECTORIS; ARTICLE; BLOOD SAMPLING; CHINESE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL ASSESSMENT; CORONARY ARTERY BYPASS GRAFT; COUNTERPULSATION; DIABETES MELLITUS; DISEASE ASSOCIATION; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; HEART ARREST; HEART DEATH; HEART INFARCTION; HISPANIC; HUMAN; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TRANSLUMINAL CORONARY ANGIOPLASTY;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ASIAN AMERICANS; COHORT STUDIES; CORONARY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SPHINGOMYELINS;

EID: 77649121670     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.199281     Document Type: Article

References (20)

1. Tabas I. Sphingolipids and atherosclerosis: a mechanistic connection? a therapeutic opportunity? Circulation. 2004;10:3400-3401.
2. Bismuth J, Lin P, Yao Q, Chen C. Ceramide a common pathway for atherosclerosis. Atherosclerosis. 2008;196:497-504.
3. Alewijnse AE, Peter SL. Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur J Pharmacol. 2008;585:292-302.
4. Smith EB. Intimal and medial lipids in human aorta. Lancet. 1960;1: 799-803.
5. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein: proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest. 1996;98:1455-1464.
6. Devlin CM, Leventhal AR, Kuriakose G, Schuchman EH, Williams KJ, Tabas I. Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol. 2008;28:1723-1730.
7. Park TS, Panek RL, Mueller SB, Hanselman JC, Rosebury WS, Robertson AW, Kindt EK, Homan R, Karathanasis SK, Rekhter MD. Inhi-bition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2004;110:3465-3471.
8. Hojjati MR, Li Z, Zhou H, Tang S, Huan C, Ooi E, Lu S, Jiang XC. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem. 2005;280:10284-10289. (Pubitemid 40395884)
9. Mukhin DN, Chao FF, Kruth HS. Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1607-1615.
10. Noel C, Marcel YL, Davignon J. Plasma phospholipids in the different types of primary hyperlipoproteinemia. J Lab Clin Med. 1972;79: 611-612.
11. Nelson JC, Jiang XC, Tabas I, Tall A, Shea S. Plasma sphingomyelin and subclinical atherosclerosis: findings from the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2006;163:903-912. (Pubitemid 43752356)
12. Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, Berglund L, Tall AR. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2000;20:2614-2618.
13. Schlitt A, Blankenberg S, Yan D, von Gizycki H, Buerke M, Werdan K, Bickel C, Lackner KJ, Meyer J, Rupprecht HJ, Jiang XC. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond). 2006;5:3-5.
14. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871-881.
15. Friedewald WF, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
16. Boston AG, Selhub J. Homocysteine and atherosclerosis: subclinical and clinical disease association. Circulation. 1999;99:2361-2363.
17. Lonn E. Homocysteine: lowering B vitamin therapy in cardiovascular prevention: wrong again? JAMA. 2008;299:2086-2087.
18. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481-3488.
19. Liu J, Huan C, Chakraborty M, Zhang H, Lu D, Kuo MS, Cao G, Jiang XC. Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice. Circ Res. 2009;105:295-303.
20. Liu J, Zhang H, Li Z, Hailemariam TK, Chakraborty M, Jiang K, Qui D, Bui HH, Peake DA, Kuo MS, Wadgaonkar R, Cao G, Jiang XC. Sphin-gomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice. Arterioscler Thromb Vasc Biol. 2009;29: 850-856.